COBI=============better side-effect profile. So, these are basically imitations of an existing product, but are designed to have the following distinguishing characteristics:
Superior Efficacy
Superior Safety
Improved Drug Delivery Characteristics Compared to the Original Product.
From a development perspective, these types of products have lower development costs and lower development risk due to well established mechanisms of action, a known safety profile, with broad clinical indications for physician use.
COBI's Top 4 Top Investor Highlights
#1. COBI has recently received proposal of a planned financing of Ten Million which is expected to tremendously jump start its operations!
#2. COBI is entering an industry with a growth prospect to more than Two Hundred Thirty Nine Billion by 2015.
#3. COBI has recently acquired an exclusive license from ARECOR LTD, from Cambridge UK!
#5. COBI is witnessing bullish technical indicators along with the “high growth” in the industry.
Why People Trade in Generic Drugs?
This week, I was determined to find a company that has been overlooked by the majority of the investor community.
The generic drug industry has been receiving enormous attention from the media recently with analysts predicting tremendous growth over the next few years…
…Analysts have forecasted for the global generic drug market to grow by more than 100% in the next few years…
Biologic Drugs are large-molecule drugs based on proteins.
Biosimilar Drugs (or follow-on biologics): are “copies” of biologic drugs that have lost patent protection.
They are distinguished from small-molecule generic drugs because of their size and complexity and that they are produced from living cells as compared to generic drugs; which are produced in a test tube.
The global biologics and biosimiliars market is valued at an estimated One Hundred Forty Nine billion in 2010 and is expected to reach Two Hundred Thirty Nine Billion by 2015.
As indicated though multiple sources, the generic drug market has been consistently growing for the past few years, with increased government support and new insurance policies.
The reason the value of the industry is expected to surge in the coming year, and has done so in the past few years is due to the overwhelming demand for these products by the consumer.
Demand for generic drugs has been consistently increasing as general practitioners, specialists, and hospitals have begun recommending generic medicines rather than the higher priced brand named pharmaceuticals.
Furthermore, generic drugs now account for 72% of the total US pharmaceutical market.
…72% is approximately $84 billion in sales, with a compound annual growth rate of 11.9%.
COBI's Competitive Growth Strategy
Garth Likes, CEO of Compass stated that by looking at generic and biosimilar opportunities, "... we do not wish to be strictly a generic drug me too company."
Rather, securing a a supply of certain products "...will allow us to add our own value, so as to create Bio-Better products and which where possible will also have their own patent protection."
You see, Bio-Betters make existing biologic drugs even better!
For example... according to Joseph Sinkule, Director of COBI, "...formulating the protein with patented polyethylene glycol (PEG) or other carriers to make the new biological drug more efficacious, or remaining in the blood longer allowing for less frequent dosing, and most critically potentially reducing the risk of immunogenicity (side effects and allergic reactions) to the protein. We have multiple strategies in play which will allow us to announce future products which will lead to nearer term revenue generation for the Company."
Mr. Likes confirmed this by the signing of an MOU with Pangen Biotech (per April 11, 2011 news announcement) that it "...opens the door for many multiple millions in revenues for the Company and expects to announce the signing of the definitive agreement shortly. "
COBI is Showing an Increase...Watch it Trade
A few days ago, COBI showed that when volume entered, it could SKYROCKET.
Since then, shares have settled and developed a base... and have also begun to show interest within the trading community by trading upwards.
So, the buzz is getting out.
Which means I believe NOW could be the time to get in.
I strongly believe we could witness further market appreciation as more traders are exposed to COBI.
The Company has been expanding and continues to offer more potentially industry leading solutions and strategies within the hot Bio-Tech Sector.
